$86.40
0.290.34%
Dernière mise à jour: 1:58 PM
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Edwards Lifesciences Corp a un objectif de cours consensuel de $90.26 basé sur les évaluations de 21 analystes. Le plus élevé est $104, publié par Goldman Sachs le octobre 31, 2025. Le plus bas est $70, publié par TD Cowen le juillet 25, 2024. Les 3 évaluations d’analystes les plus récentes ont été publiées par Truist Securities, Canaccord Genuity et Barclays le novembre 3, 2025, novembre 3, 2025 et octobre 31, 2025, respectivement. Avec un objectif de cours moyen de $91 entre Truist Securities, Canaccord Genuity et Barclays, il existe une variation implicite de 5.34% upside pour Edwards Lifesciences Corp selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Truist Securities
Canaccord Genuity
Barclays
Citigroup
JP Morgan
1calculé à partir des notes des analystes
Notes d'analystes pour Edwards Lifesciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/03/2025 | 4.18% | Truist Securities | $87 → $90 | Maintains | Hold | |||
11/03/2025 | -2.76% | Canaccord Genuity | $81 → $84 | Maintains | Hold | |||
10/31/2025 | 14.6% | Barclays | $95 → $99 | Maintains | Overweight | |||
10/31/2025 | 11.13% | Citigroup | $95 → $96 | Maintains | Buy | |||
10/31/2025 | 4.18% | JP Morgan | $85 → $90 | Maintains | Neutral | |||
10/31/2025 | 20.39% | Goldman Sachs | $94 → $104 | Maintains | Buy | |||
10/31/2025 | 9.97% | Piper Sandler | $90 → $95 | Reiterates | Overweight → Overweight | |||
10/31/2025 | 9.97% | RBC Capital | $89 → $95 | Maintains | Outperform | |||
10/31/2025 | 9.97% | Stifel | $85 → $95 | Maintains | Buy | |||
10/31/2025 | 6.5% | Evercore ISI Group | $88 → $92 | Maintains | Outperform | |||
10/31/2025 | 15.76% | Mizuho | $90 → $100 | Maintains | Outperform | |||
10/29/2025 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
10/29/2025 | 13.45% | Jefferies | $80 → $98 | Upgrade | Hold → Buy | |||
10/28/2025 | 0.71% | Truist Securities | $82 → $87 | Maintains | Hold | |||
10/08/2025 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
10/07/2025 | 1.87% | Evercore ISI Group | $80 → $88 | Upgrade | In-Line → Outperform | |||
09/22/2025 | -1.6% | Stifel | $95 → $85 | Maintains | Buy | |||
08/07/2025 | 1.87% | Wells Fargo | $84 → $88 | Maintains | Overweight | |||
07/25/2025 | -1.6% | JP Morgan | $80 → $85 | Maintains | Neutral | |||
07/25/2025 | -6.23% | Canaccord Genuity | $75 → $81 | Maintains | Hold | |||
07/25/2025 | 9.97% | Mizuho | $87 → $95 | Maintains | Outperform | |||
07/25/2025 | -5.08% | Truist Securities | $81 → $82 | Maintains | Hold | |||
07/25/2025 | 9.97% | Stifel | $90 → $95 | Maintains | Buy | |||
07/25/2025 | 9.97% | Barclays | $90 → $95 | Maintains | Overweight | |||
07/25/2025 | 4.18% | Piper Sandler | $83 → $90 | Maintains | Overweight | |||
07/25/2025 | 3.03% | RBC Capital | $85 → $89 | Maintains | Outperform | |||
07/25/2025 | -2.76% | Wells Fargo | $80 → $84 | Maintains | Overweight | |||
07/25/2025 | -7.39% | Evercore ISI Group | $77 → $80 | Maintains | In-Line | |||
07/25/2025 | 8.82% | Deutsche Bank | $85 → $94 | Maintains | Buy | |||
07/25/2025 | -8.55% | Baird | $78 → $79 | Maintains | Neutral | |||
07/16/2025 | 0.71% | Mizuho | $85 → $87 | Maintains | Outperform | |||
07/15/2025 | -6.23% | Morgan Stanley | $75 → $81 | Maintains | Equal-Weight | |||
07/08/2025 | -10.86% | Evercore ISI Group | $73 → $77 | Maintains | In-Line | |||
05/22/2025 | 9.97% | Citigroup | $84 → $95 | Maintains | Buy | |||
05/13/2025 | -3.92% | Piper Sandler | $80 → $83 | Maintains | Overweight | |||
04/25/2025 | -13.18% | Canaccord Genuity | $71 → $75 | Maintains | Hold | |||
04/24/2025 | -7.39% | Piper Sandler | $73 → $80 | Upgrade | Neutral → Overweight | |||
04/24/2025 | -13.18% | Baird | $72 → $75 | Maintains | Neutral | |||
04/11/2025 | -13.18% | Truist Securities | $78 → $75 | Maintains | Hold | |||
02/13/2025 | 4.18% | Barclays | $88 → $90 | Maintains | Overweight | |||
02/13/2025 | -17.81% | Canaccord Genuity | $68 → $71 | Maintains | Hold | |||
02/12/2025 | -1.6% | RBC Capital | $85 → $85 | Reiterates | Outperform → Outperform | |||
02/12/2025 | -15.49% | Piper Sandler | $70 → $73 | Maintains | Neutral | |||
02/12/2025 | -15.49% | Evercore ISI Group | $75 → $73 | Maintains | In-Line | |||
02/12/2025 | -13.18% | Morgan Stanley | $70 → $75 | Maintains | Equal-Weight | |||
01/30/2025 | 4.18% | Stifel | $75 → $90 | Upgrade | Hold → Buy | |||
01/16/2025 | -30.54% | Wolfe Research | $60 → $60 | Downgrade | Peer Perform → Underperform | |||
12/16/2024 | 4.18% | B of A Securities | $82 → $90 | Upgrade | Neutral → Buy | |||
12/11/2024 | -3.92% | Citigroup | $81 → $83 | Maintains | Buy | |||
12/05/2024 | 4.18% | Goldman Sachs | $81 → $90 | Maintains | Buy | |||
12/05/2024 | -9.71% | Truist Securities | $70 → $78 | Reiterates | Hold → Hold | |||
12/05/2024 | -13.18% | Stifel | $70 → $75 | Maintains | Hold | |||
12/05/2024 | -1.6% | RBC Capital | $80 → $85 | Maintains | Outperform | |||
12/05/2024 | -21.28% | Canaccord Genuity | $63 → $68 | Maintains | Hold | |||
12/02/2024 | 1.87% | Barclays | $85 → $88 | Maintains | Overweight | |||
11/27/2024 | -7.39% | RBC Capital | $75 → $80 | Maintains | Outperform | |||
10/25/2024 | -27.07% | Canaccord Genuity | $66 → $63 | Maintains | Hold | |||
10/25/2024 | -9.71% | JP Morgan | $72 → $78 | Maintains | Neutral | |||
10/25/2024 | -18.97% | Piper Sandler | $73 → $70 | Maintains | Neutral | |||
10/25/2024 | -18.97% | Truist Securities | $71 → $70 | Maintains | Hold | |||
10/25/2024 | -21.28% | Baird | $73 → $68 | Maintains | Neutral | |||
10/11/2024 | -18.97% | Morgan Stanley | → $70 | Reinstates | → Equal-Weight | |||
10/08/2024 | -13.18% | RBC Capital | $85 → $75 | Maintains | Outperform | |||
10/07/2024 | -23.6% | Canaccord Genuity | $77 → $66 | Maintains | Hold | |||
10/01/2024 | -18.97% | Evercore ISI Group | $76 → $70 | Maintains | In-Line | |||
10/01/2024 | -10.86% | Citigroup | $83 → $77 | Maintains | Buy | |||
09/18/2024 | -18.97% | Jefferies | $85 → $70 | Downgrade | Buy → Hold | |||
09/13/2024 | -17.81% | Truist Securities | $82 → $71 | Maintains | Hold | |||
09/12/2024 | 4.18% | Oppenheimer | $90 → $90 | Maintains | Outperform | |||
09/10/2024 | -13.18% | UBS | $90 → $75 | Maintains | Neutral | |||
09/09/2024 | -7.39% | Barclays | $90 → $80 | Maintains | Overweight | |||
09/09/2024 | -7.39% | Wells Fargo | $90 → $80 | Maintains | Overweight | |||
07/29/2024 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
07/26/2024 | 4.18% | Barclays | $101 → $90 | Maintains | Overweight | |||
07/26/2024 | 5.34% | Goldman Sachs | $107 → $91 | Maintains | Buy | |||
07/25/2024 | -18.97% | TD Cowen | $100 → $70 | Downgrade | Buy → Hold | |||
07/25/2024 | 4.18% | Wells Fargo | $99 → $90 | Maintains | Overweight | |||
07/25/2024 | -12.02% | Evercore ISI Group | $91 → $76 | Maintains | In-Line | |||
07/25/2024 | -1.6% | Deutsche Bank | $103 → $85 | Maintains | Buy | |||
07/25/2024 | -1.6% | RBC Capital | $101 → $85 | Maintains | Outperform | |||
07/25/2024 | -5.08% | Truist Securities | $110 → $82 | Downgrade | Buy → Hold | |||
07/25/2024 | -18.97% | Stifel | $85 → $70 | Maintains | Hold | |||
07/25/2024 | 4.18% | Oppenheimer | $100 → $90 | Maintains | Outperform | |||
07/25/2024 | -10.86% | Canaccord Genuity | $85 → $77 | Maintains | Hold | |||
07/25/2024 | -15.49% | Piper Sandler | $88 → $73 | Maintains | Neutral | |||
07/25/2024 | -13.18% | B of A Securities | $105 → $75 | Downgrade | Buy → Neutral | |||
07/25/2024 | -16.65% | JP Morgan | $105 → $72 | Downgrade | Overweight → Neutral | |||
07/25/2024 | -18.97% | Baird | $102 → $70 | Downgrade | Outperform → Neutral | |||
07/16/2024 | 27.34% | Truist Securities | $105 → $110 | Maintains | Buy | |||
07/10/2024 | 22.71% | Citigroup | $105 → $106 | Maintains | Buy | |||
07/02/2024 | 5.34% | Evercore ISI Group | $89 → $91 | Maintains | In-Line | |||
05/30/2024 | 23.86% | Goldman Sachs | → $107 | Initiates | → Buy | |||
05/22/2024 | 21.55% | Citigroup | $98 → $105 | Upgrade | Neutral → Buy | |||
05/14/2024 | 19.23% | Deutsche Bank | $86 → $103 | Upgrade | Hold → Buy | |||
05/07/2024 | 16.92% | Barclays | $100 → $101 | Maintains | Overweight | |||
04/26/2024 | -1.6% | Canaccord Genuity | $86 → $85 | Maintains | Hold | |||
04/26/2024 | 14.6% | Wells Fargo | $94 → $99 | Maintains | Overweight | |||
04/26/2024 | 3.03% | Evercore ISI Group | $92 → $89 | Maintains | In-Line | |||
04/26/2024 | -1.6% | Stifel | $83 → $85 | Maintains | Hold | |||
04/26/2024 | 1.87% | Piper Sandler | $85 → $88 | Maintains | Neutral |
FAQ
Quel est le cours indicatif de l'action Edwards Lifesciences (EW) ?
Le dernier objectif de prix pour Edwards Lifesciences (NYSE:EW) a été rapporté par Truist Securities le novembre 3, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $90.00 s'attendant à ce que EW se rise dans les 12 prochains mois (un possible changement de 4.17% upside). 56 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Edwards Lifesciences (EW) ?
La dernière note d'analyste pour Edwards Lifesciences (NYSE:EW) a été fournie par Truist Securities, et Edwards Lifesciences maintenu leur note hold.
Quand a eu lieu la dernière mise à niveau pour Edwards Lifesciences (EW) ?
La dernière amélioration pour Edwards Lifesciences Corp a eu lieu le octobre 29, 2025 lorsque Wolfe Research a augmenté leur objectif de prix à N/A. Wolfe Research avait précédemment an underperform pour Edwards Lifesciences Corp.
Quand a eu lieu la dernière dégradation pour Edwards Lifesciences (EW) ?
La dernière réduction pour Edwards Lifesciences Corp a eu lieu le octobre 8, 2025 lorsque Oppenheimer a changé leur objectif de prix de N/A à N/A pour Edwards Lifesciences Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Edwards Lifesciences (EW) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Edwards Lifesciences, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Edwards Lifesciences a été déposée le novembre 3, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 3, 2026.
La note d'analyste pour Edwards Lifesciences (EW) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Edwards Lifesciences (EW) était un maintenu avec un objectif de prix de $87.00 à $90.00. Le prix actuel de Edwards Lifesciences (EW) est de $86.40, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.